FindTrial
Sign In

The Inflammatory Burden in Hemodialysis vs. Peritoneal Dialysis Patients: the Role of Alpha-defensin

The Inflammatory Burden in Hemodialysis vs. Peritoneal Dialysis Patients: the Role of Alpha-defensin

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03845530
Enrollment
80
Registered
2019-02-19
Start date
2019-03-31
Completion date
2020-03-31
Last updated
2019-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Kidney Failure

Brief summary

The aim of this study is to determine the levels of alpha-defensin throughout the hemodialysis course compared to the levels at the end of a course of peritoneal dialysis, as a reflection of the inflammatory burden.

Interventions

DIAGNOSTIC_TESTBlood Test

Blood test taken and sent for laboratory analysis

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Kidney failure patients undergoing hemodialysis or peritoneal dialysis

Exclusion criteria

* Active inflammatory or infectious disease

Design outcomes

Primary

MeasureTime frameDescription
Alpha-Defensin LevelsOne yearAlpha-defensin levels will be compared between the two arms

Countries

Israel

Contacts

Primary ContactRami Abu Fanne, MD, PhD
ramia@hadassah.org.il972-50-3573694

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026